Human iPSC-derived vascular-related and hematopoetic cells for therapies and toxicology/drug screenings
Manfred Boehm, Bethesda, MD (US); Guibin Chen, Ellicott City, MD (US); Mahendra Rao, Timonium, MD (US); and Andre Larochelle, Bethesda, MD (US)
Assigned to The USA, as represented by the Secretary, Dept. of Health and Human Services, Bethesda, MD (US)
Filed by The USA, as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US)
Filed on Jun. 3, 2021, as Appl. No. 17/337,978.
Application 16/544,381 is a division of application No. 15/026,313, granted, now 10,385,313, issued on Aug. 20, 2019, previously published as PCT/US2014/058583, filed on Oct. 1, 2014.
Application 17/337,978 is a continuation of application No. 16/544,381, filed on Aug. 19, 2019, granted, now 11,072,778.
Claims priority of provisional application 61/885,209, filed on Oct. 1, 2013.
Prior Publication US 2021/0348123 A1, Nov. 11, 2021
1. A method of treating a subject for a congenital bone marrow disorder, comprising administering to the subject an iPSC-derived mesodermal precursor cell, comprising a mesodermal precursor cell expressing CD34 and CD31 on its cell surface, wherein the mesodermal precursor cell is capable of differentiating into a hematopoietic stem cell.